Literature DB >> 8087923

Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans.

D L Vesely1, M A Douglass, J R Dietz, W R Gower, M T McCormick, G Rodriguez-Paz, D D Schocken.   

Abstract

BACKGROUND: Three peptides consisting of amino acids 1-30, 31-67, and 79-98 of the 126-amino acid atrial natriuretic factor prohormone (proANF), which have blood pressure-lowering, diuretic, natriuretic, and/or kaliuretic properties in animals, were investigated to determine if they have similar properties in humans. METHODS AND
RESULTS: Thirty-six healthy, normotensive human volunteers (18 men and 18 women, ages 20 to 58 years) were divided into six similar groups based on age, sex, weight, blood pressure, and heart rate. After a 60-minute baseline period, 100 ng of proANFs 1-30, 31-67, 79-98, or ANF/kg body wt per minute was given intravenously for 60 minutes followed by a 3-hour postinfusion data collection period. Each of the atrial natriuretic peptides decreased systolic and diastolic blood pressures (P < .05), with proANF 31-67 causing the largest decrease. Urine flow increased 4- to 12-fold and was still significantly increased (P < .01) for 2 to 3 hours after stopping the respective infusions of proANFs 1-30, 31-67, and 79-98. Atrial natriuretic factor (ANF) increased urine flow 4- to 11-fold but by 2 hours after infusion was significantly increased in only 1 of 6 subjects. Sodium excretion increased 3- to 8-fold, 3- to 6-fold, 0- to 2-fold (NS), and 3- to 11-fold, respectively, with proANFs 1-30, 31-67, 79-98, and ANF. Natriuretic effects of proANFs 1-30 and 31-67 were significantly prolonged (P < .001) compared with ANF. ProANFs 1-30, 31-67, 79-98, and ANF increased potassium excretion 2- to 3-fold, 0-fold, 3- to 4-fold, and 2-fold, respectively. High-performance gel permeation chromatography followed by the respective radioimmunoassays revealed that proANFs 1-30, 31-67, 79-98, and 68-98, as well as ANF circulate as distinct peptides.
CONCLUSIONS: ProANFs 1-30, 31-67, and 79-98, as well as ANF have significant blood pressure-lowering and diuretic properties. ProANFs 1-30 and 31-67 also have natriuretic properties in humans that are significantly (P < .001) prolonged compared with ANF. ProANF 79-98, although not possessing any natriuretic property, is the strongest stimulator of potassium excretion of the four atrial natriuretic peptides.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8087923     DOI: 10.1161/01.cir.90.3.1129

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  22 in total

1.  Possibility of age regulation of the natriuretic peptide C-receptor in human platelets.

Authors:  D Giannessi; M G Andreassi; S Del Ry; A Clerico; M G Colombo; N Dini
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

2.  Four cardiac hormones increase circulating concentrations of luteinizing hormone and testosterone.

Authors:  David L Vesely; Gloria I San Miguel; Imran Hassan; William R Gower; Douglas D Schocken
Journal:  Endocrine       Date:  2002-03       Impact factor: 3.633

3.  Kaliuretic nonapeptide.

Authors:  A V Kutina; A S Marina; M I Titov; Yu V Natochin
Journal:  Dokl Biol Sci       Date:  2012-07-05

4.  The heart communicates with the kidney exclusively through the guanylyl cyclase-A receptor: acute handling of sodium and water in response to volume expansion.

Authors:  I Kishimoto; S K Dubois; D L Garbers
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

5.  Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via cyclic GMP.

Authors:  William R Gower; Brian A Vesely; Abdel A Alli; David L Vesely
Journal:  Int J Gastrointest Cancer       Date:  2005

Review 6.  Natriuretic Peptides and Cardiometabolic Health.

Authors:  Deepak K Gupta; Thomas J Wang
Journal:  Circ J       Date:  2015-06-23       Impact factor: 2.993

7.  Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis.

Authors:  A Clerico; R Caprioli; S Del Ry; D Giannessi
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

8.  Atrial natriuretic hormone prohormone gene expression in cardiac and extra-cardiac tissues of diabetic Goto-Kakizaki rats.

Authors:  William R Gower; Gloria I San Miguel; Gay M Carter; Imran Hassan; Robert V Farese; David L Vesely
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

Review 9.  B-type natriuretic peptide: physiologic role and assay characteristics.

Authors:  Hassan M E Azzazy; Robert H Christenson
Journal:  Heart Fail Rev       Date:  2003-10       Impact factor: 4.214

Review 10.  Urodilatin: a better natriuretic peptide?

Authors:  David L Vesely
Journal:  Curr Heart Fail Rep       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.